47 Autoantibodies pANCA Lysosomal enzymes present in the cytoplasm of neutrophils and monocytes UC Disease activity, colonic disease involvement (in CD) Anti-GP2 Glycoprotein 2, membrane receptor located in M-cells of (small) intestinal Peyer’s patches CD Ileal disease involvement, early disease onset, long disease duration, stricturing phenotype, perianal disease Anti-CUZD1 CUB and zona pellucida-like domains 1, regulating immunological tolerance CD Ileal disease involvement, perianal disease Anti-IFI16 IFI16 protein, belongs to the PYHIN-200 family of pattern recognition receptors CD Non-response to TNF-αantagonists Anti-MZGP2 Major zymogen glycoprotein 2 CD Ileal disease involvement, early disease onset, long disease duration Anti-CHI3L1 Chitinase-3-like protein 1 CD Aggressive, complicated disease Anti-GM-CSF Granulocyte macrophage colonystimulating factor CD Ileal disease involvement, aggressive disease Anti-ACA Anti-cardiolipin CD Use of TNF-α-antagonists Anti-PS/PT Phosphatidylserine/prothrombin CD Use of TNF-α-antagonists Anti-GBA Goblet cells UC - Abbreviations: ACA, anti-cardiolipin; ACCA, anti-chitobioside carbohydrate antibodies; ALCA, anti-laminaribioside carbohydrate antibodies; AMCA, anti-mannobioside carbohydrate antibodies; Anti-C, anti-chitin antibodies; AntiCBir1, anti-flagellin CBir1 antibodies; Anti-I2, antimicrobial sequence I2 antibodies; Anti-L, anti-laminarin antibodies; ASCA, anti-Saccharomyces cerevisiae antibodies; GBA, goblet cell antibodies; GM-CSF, granulocyte/monocyte colony-stimulating factor; GP2, (pancreatic) glycoprotein 2; MAP, Mycobacterium avium subspecies paratuberculosis; MZGP2, major zymogen glycoprotein 2; OmpC, outer membrane protein of Escherichia coli; pANCA, perinuclear anti-neutrophil cytoplasmic antibodies; PS, phosphatidylserine; PT, prothrombin; CD, Crohn’s disease; CHI3L1, chitinase 3-like protein 1; CUZD1, CUB and zona pellucida-like domains 1; UC, ulcerative colitis; IBD, inflammatory bowel disease. Abbreviations: ACA, anti-cardiolipin; ACCA, anti-chitobioside carbohydrate antibodies; ALCA, anti- laminaribioside carbohydrate antibodies; AMCA, anti-mannobioside carbohydrate antibodies; Anti-C, antichitin antibodies; Anti-CBir1, anti-flagellin CBir1 antibodies; Anti-I2, antimicrobial sequence I2 antibodies; Anti-L, anti-laminarin antibodies; ASCA, anti-Saccharomyces cerevisiae antibodies; GBA, goblet cell antibodies; GM-CSF, granulocyte/monocyte colony-stimulating factor; GP2, (pancreatic) glycoprotein 2; MAP, Mycobacterium avium subspecies paratuberculosis; MZGP2, major zymogen glycoprotein 2; OmpC, outer membrane protein of Escherichia coli; pANCA, perinuclear anti-neutrophil cytoplasmic antibodies; PS, phosphatidylserine; PT, prothrombin; CD, Crohn’s disease; CHI3L1, chitinase 3-like protein 1; CUZD1, CUB and zona pellucida-like domains 1; UC, ulcerative colitis; IBD, inflammatory bowel disease. Serological Antibodies in IBD: Clinical Utility and Phenotypic Associations Disease diagnosis and classification In clinical practice, some serological antibodies may support the diagnosis and classification of IBD, but their diagnostic accuracy is generally considered too limited for conclusive differentiation between CD and UC.10 To date, no single serological indicator exists that is useful for diagnosing CD or UC. ASCA and pANCA are the most commonly known and best available serological markers with a relatively high specificity but poor sensitivity. Albeit moderate, their diagnostic utility seems to be higher in pediatric patients with IBD than in adult patients.28,29 Similarly, the additional value of antimicrobial antibodies, e.g. anti-CBir1 and anti-OmpC, in differentiating Antibody signatures in IBD: developments and applications
RkJQdWJsaXNoZXIy MjY0ODMw